Bayforest Capital Ltd Boosts Holdings in Lantheus Holdings, Inc. $LNTH

Bayforest Capital Ltd lifted its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 258.5% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 11,152 shares of the medical equipment provider’s stock after buying an additional 8,041 shares during the quarter. Bayforest Capital Ltd’s holdings in Lantheus were worth $572,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Harbor Capital Advisors Inc. lifted its stake in shares of Lantheus by 24.7% in the 2nd quarter. Harbor Capital Advisors Inc. now owns 190,008 shares of the medical equipment provider’s stock valued at $15,554,000 after purchasing an additional 37,691 shares during the period. Reinhart Partners LLC. raised its holdings in Lantheus by 16.4% in the second quarter. Reinhart Partners LLC. now owns 1,403,659 shares of the medical equipment provider’s stock worth $114,905,000 after purchasing an additional 197,719 shares in the last quarter. Stanley Laman Group Ltd. raised its holdings in Lantheus by 38.7% in the third quarter. Stanley Laman Group Ltd. now owns 79,686 shares of the medical equipment provider’s stock worth $4,087,000 after purchasing an additional 22,229 shares in the last quarter. Swedbank AB lifted its position in Lantheus by 11.0% during the first quarter. Swedbank AB now owns 1,228,743 shares of the medical equipment provider’s stock valued at $119,925,000 after buying an additional 121,500 shares during the period. Finally, Strs Ohio bought a new stake in shares of Lantheus during the 1st quarter valued at $4,529,000. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on LNTH shares. Weiss Ratings upgraded shares of Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday. B. Riley decreased their target price on shares of Lantheus from $109.00 to $84.00 and set a “buy” rating for the company in a research note on Tuesday, September 16th. The Goldman Sachs Group set a $77.00 price target on Lantheus and gave the stock a “neutral” rating in a research report on Wednesday, October 8th. Truist Financial upped their price target on Lantheus from $80.00 to $82.00 and gave the stock a “buy” rating in a research note on Thursday, December 18th. Finally, TD Cowen dropped their target price on Lantheus from $95.00 to $80.00 and set a “buy” rating on the stock in a report on Monday, September 15th. Five equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, Lantheus presently has an average rating of “Moderate Buy” and a consensus price target of $78.00.

Lantheus Price Performance

Shares of NASDAQ LNTH opened at $67.56 on Friday. The firm has a market cap of $4.48 billion, a P/E ratio of 28.39 and a beta of -0.11. Lantheus Holdings, Inc. has a twelve month low of $47.25 and a twelve month high of $111.29. The company has a quick ratio of 2.49, a current ratio of 2.67 and a debt-to-equity ratio of 0.51. The company has a 50 day moving average of $61.15 and a 200 day moving average of $61.42.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Tuesday, May 17th. The medical equipment provider reported $0.05 EPS for the quarter. The business had revenue of $92.51 million during the quarter. Lantheus had a return on equity of 30.88% and a net margin of 10.99%.Lantheus has set its FY 2025 guidance at 5.500-5.650 EPS. As a group, research analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.